Here I am presenting my work, it’s about tumour control probability for prostate cancer patients.

What does your job involve?

Basically, what I am doing is creating a TCP model, tumour control probability model, then we incorporate some biological information into that model, in particular we incorporate the cell number for the tumour and then we try to evaluate the survival fraction and the tumour control probability.

Does this help the patient?

It’s still in the early stage and we are trying to develop more MRI sequences to get more cell right information to incorporate also into the TCP model. So finally our aim is to incorporate in the clinics and get a better treatment for the patients, of course.

What would be the standard that you compare it with?

Right now we are trying to compare the results with the dose escalation protocol and also with a homogeneous dose protocol for prostate cancer patients with external beam radiotherapy.

Can this be applied to other cancers?

Actually we are not trying to do outside the prostate but of course it’s something that you can apply somewhere else.